蔣智宏^1,2、洪健華²、黃昭淵²

¹臺北榮民總醫院員山分院 泌尿外科

²臺灣大學附設醫院 泌尿部

Public Chinese Prostate Cancer Professional Series-3：Updated Treatment for non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) (translated from NCCN Prostate Cancer Guidelines 2023 V1)

Chih-Hung Chiang^1,2、Jian‑Hua Hong²、Chao‑Yuan Huang²

¹ Department of Urology, Taipei Veterans General Hospital, Yuan-Shan Branch；

² Departments of Urology, National Taiwan University Hospital

Purpose：There are few specialized Chinese series on prostate cancer (PCa). This article is completely translated into Chinese according to the NCCN PCa Guideline Version 1. 2023. It is hoped that through the clear and easy-to-understand professional Chinese PCa series introduction, patients and their families can get the most correct and complete understanding from accurate biopsy diagnosis to the latest PCa treatment methods.

Materials and Methods：This section, non-metastatic Castration-Resistant Prostate Cancer (nmCRPC), is translated from the NCCN PCa Guidelines Versions 1. 2023.

Results：Androgen Deprivation Therapy (Maintain castration level of testosterone <50 ng/dL) + Apalutamide or Darolutamide or Enzalutamide($) are the best combination recommended for nmCRPC with PSA doubling time £ 10 months. However, if nmCRPC with PSA doubling time > 10 months, Androgen Deprivation Therapy (Maintain castration level of testosterone <50 ng/dL) + observation is the most recommended treatment combination.

Conclusion：Objective PSA doubling time and adequate communication are the key to the treatment selection of "non-metastatic Castration-Resistant PCa".